Insights from 2023 ESMO Annual Meeting
J

Adjuvant Abemaciclib + Endocrine Therapy for HR+, HER2- High-Risk eBC: Results From a Preplanned monarchE OS Interim Analysis, Including 5-Year Efficacy Outcomes

By Insights from 2023 ESMO Annual Meeting FEATURING Jens Huober
By Insights from 2023 ESMO Annual Meeting FEATURING Jens Huober
1,456 views
December 4, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Related Content

AUTOPLAY
25:08
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo
12:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…

Feat. P. Tarantino
11:31
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …

Feat. P. Tarantino
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
07:23
Total Health

Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…

Feat. R. O'Regan
03:40
Integrity CE

SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …

Feat. A. Bardia
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
17:39
Yale School of Medicine

2023 Menopause Update

Feat. M. Minkin
10:53
Kirollos Hanna

Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC

28:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "eBC Expert Panel Discussion on Key Trials …

Feat. H. Rugo, K. Jhaveri
05:43
Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma
17:20
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…

Feat. P. Tarantino
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
27:01
Scripps Health

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Feat. S. Sammons
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
10:34
Sara Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo
36:18
Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo
33:44
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…

Feat. S. Tolaney, H. Rugo
16:19
Wassim Mchayleh

Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…

10:27
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…

Feat. S. Tolaney, H. Rugo